Geben Sie eine Aktie oder eine Kryptowährung in der Suchleiste an, um eine Zusammenfassung zu erhalten
Aurobindo Pharma Limited
AUROPHARMAAurobindo Pharma Limited, a biopharmaceutical company, engages in the manufacture of generic formulations and active pharmaceutical ingredients in India, the United States of America, Europe, Puerto Rico, and internationally. The company offers formulation in form of oral solids, liquids, injectables, and vaccines, as well as over-the-counter drugs; and active pharmaceutical ingredients (APIs), biosimilars, biocatalysts, peptides, and hormones targeting key therapeutic areas, including central nervous system, cardiovascular, respiratory, antibiotics, anti-retroviral, anti-diabetics, gastroenterology, oncology, and dermatology. It also provides antiretroviral drugs for the people and children living with HIV; and provides project-based chemistry contract services that cover the clinical stage through to manufacturing and management of the entire drug lifecycle in the API space for sterile and non-sterile penicillin's, cephalosporins, penems, and non-beta lactams. The company was incorporated in 1986 and is headquartered in Hyderabad, India. Address: Galaxy, Plot No. 1, Hyderabad, India, 500032
Analytics
Zielpreis von Wall Street
80 407.42 INRKGV
23.2011Dividendenrendite
0.34 %Laufendes Jahr
Letztes Jahr
Laufendes Quartal
Letztes Quartal
Laufendes Jahr
Letztes Jahr
Laufendes Quartal
Letztes Quartal
Schlüsselzahlen AUROPHARMA
Dividenden-Analyse AUROPHARMA
Dividendenwachstum über 5 Jahre
167 %Kontinuierliches Wachstum
–Ausschüttungsquote 5-Jahres-Durchschnitt
10 %Verlauf der Dividende AUROPHARMA
Bewertung der Aktie AUROPHARMA
Finanzen AUROPHARMA
Ergebnisse | 2019 | Dynamik |